Arecor Therapeutics PLC (LON:AREC)
64.25p+2.80%
Spriggl Score: Poor— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Ultra-concentrated insulin platform offers optionality but cash runway ends May 2027 before Phase II trials begin.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Arecor Therapeutics PLC
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform …
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £22.8M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Arecor Therapeutics PLC and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free